SCM
VYNE icon

Silverarc Capital Management’s VYNE Therapeutics VYNE Stock Holding History

Silverarc Capital Management’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-76,784
Closed -$144K – 81
2024
Q3 		$144K Sell
76,784
-390,613
-84% -$740K 0.03% 70
2024
Q2 		$921K Buy
467,397
+381,014
+441% +$950K 0.22% 58
2024
Q1 		$265K Buy
+86,383
New +$186K 0.07% 72
2021
Q1 		– Sell
-4,856
Closed -$552K – 102
2020
Q4 		$552K Buy
+4,856
New +$610K 0.32% 69

Other funds holding VYNE

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Silverarc Capital Management's VYNE Position: Q4 2024 in Review

Silverarc Capital Management sold out of VYNE Therapeutics (VYNE) in Q4 2024, closing a stake of 76,784 shares — an estimated $144K sold.

Silverarc Capital Management first reported a position in VYNE in Q4 2020 and held it in 4 quarters. The position peaked at $921K in Q2 2024. 35 funds tracked by Wall St. Rank hold VYNE as of Q4 2024.

  • Silverarc Capital Management reported no remaining VYNE Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 76,784 VYNE Therapeutics shares in Q4 2024, an estimated $144K.
  • Silverarc Capital Management first reported a position in VYNE Therapeutics in Q4 2020 and held it in 4 quarters.
  • Silverarc Capital Management's VYNE Therapeutics position peaked at $921K in Q2 2024.
  • 35 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2024.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.